Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction
Jean M Ruddy1, Anne Kroman2, Catalin F Baicu2
1Division of Vascular Surgery, Department of Surgery, Medical University of South Carolina, 30 Courtenay Drive, Charleston, SC 29425, USA; Ralph H Johnson Department of Veterans Affairs Health Care System, 109 Bee Street, Charleston, SC 29401, USA.
Abstract:
A randomized, controlled trial of baroreflex activation therapy (BAT) in patients with heart failure and reduced ejection fraction demonstrated that BAT was safe and significantly improved patient-centered symptomatic outcomes, increasing exercise capacity, improving quality of life, decreasing n-terminal pro B-type natriuretic peptide (NT-proBNP), and improving functional class. BAT was approved by the FDA for improvement of symptoms of heart failure for patients who remain symptomatic despite treatment with guideline-directed management, are New York Heart Association Class III or Class II (with a recent history of Class III), have a left ventricular ejection fraction ≤ 35%, an NT-proBNP < 1600 pg/mL and excluding patients indicated for cardiac resynchronization therapy.
More Related Videos
09:56Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice
Published on: February 14, 2021
06:30Complete and Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Hemorrhagic Shock
Published on: May 19, 2022
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: β-Blockers
Heart Failure II: Pathophysiology
Aortic Regurgitation III: Medical Management
